Pregnancy and fertility

The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.

This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...

This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...

This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...

People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...

The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...

Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....

Keeping IBD well controlled before and during pregnancy lowers the risk of adverse outcomes for both parent and baby; understanding which medications are safe and which should be stopped is crucial for family planning.

People with IBD and other IMIDs often need ongoing medication during pregnancy.

Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Pregnancy and fertility. The original article is from hmpgloballearningnetwork.com.

Cure8 found this source from Inflammatory bowel diseases, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Pregnancy and fertility. Open the original article for the full...

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...

This helps people with IBD and their care teams make delivery plans: if perianal disease is not active, having IBD alone was not linked to higher perineal injury risk in first-time vaginal births in this study.

People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.

People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...

An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...

Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...

High and rising out-of-pocket costs can force people with Crohn’s disease to worry about medical debt, skip care, or make major life changes. Policy choices about insurance coverage (like Medicaid expansion) can...

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...

People with UC who need biologic therapy during conception or pregnancy often face limited evidence about safety and effectiveness; this case suggests ustekinumab may be an option when other drugs fail or are stopped for...

An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...

Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...

The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK...

The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...

This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...

The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.

This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.

This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...

This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....

Pregnancy planning affects disease and pregnancy outcomes in Crohn’s. Staying in remission and maintaining needed IBD medications during pregnancy reduces risks to both mother and baby, while stopping certain drugs...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from jnj.com.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Pregnancy and fertility. The original article is from cureus.com.

Women with Crohn’s can face specific reproductive, sexual, and body-image issues that affect quality of life and pregnancy planning. Understanding how disease activity and medications interact with fertility and...

Cure8 could only read part of this source from sundayworld.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Pregnancy and fertility.

Women with Crohn’s may have additional or different symptoms (period changes, painful sex, fertility concerns, bone and iron problems) that can affect daily life and long-term health. Recognizing these issues helps guide...

Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...

The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....

This study suggests a Crohn's genetic risk factor can change pregnancy-related gut microbiome shifts and increase inflammatory signals in mice — which could help researchers look for microbial biomarkers that predict...